19 Mar Compugen and BMS Launch New Triple Combination Therapy for Advanced Tumors
Posted at 19:38h
in Author Interviews, Bristol Myers Squibb, Cancer Research, Pharmaceutical Companies
MedicalResearch.com Interview with:
Anat Cohen-Dayag, Ph.D.
President and CEO
Compugen
MedicalResearch.com: What is the background for this announcement? Would you discuss Compugen’s underlying cancer hypothesis regarding the targeting of multiple checkpoint pathways to enhance tumor response?
Response: Cancer immunotherapy has revolutionized the landscape for cancer treatments by providing new drug options leading to lasting benefits for patients. Yet, response rates vary greatly across different cancer indications, leaving a significant unmet medical need for many patients and a continuing challenge to discover new biological pathways that can serve for the development of new cancer immunotherapies for non-responsive and refractory patients.
Using a computational approach which is designed to discover new biological pathways and drug targets, we identified PVRIG as a novel immune checkpoint and a newly discovered inhibitory pathway in the DNAM axis. Our hypothesis is that PVRIG and TIGIT (another inhibitory pathway discovered by us and others) are two parallel and complementary inhibitory pathways in the DNAM axis and that in certain tumor types and patient populations, there may be a need to block both PVRIG and TIGIT in order to enhance anti-tumor immune responses. Moreover, reported molecular intersections between the DNAM axis and the PD-1 pathway, the most prevalent pathway targeted by approved immunotherapies, suggest that there is a linkage between these three pathways. As such, our PVRIG inhibitor may work in synergy with PD-1 and TIGIT inhibitors, suggesting that various drug combinations may be required to address these three pathways based on their dominance in different cancer patients and cancer indications. With this recently announced Phase 1/2 triple combination study, we will be directly testing our hypothesis of an intersection between the three parallel immune checkpoint pathways – PVRIG, TIGIT and PD-1 – and that the simultaneous blockade of these pathways has the potential to synergistically enhance anti-tumor immune response and expand the reach of cancer immunotherapy to patients non-responsive or refractory to approved immunotherapies.

Adawiyah Jami[/caption]
Adawiyah Jamil, AdvMDerm
Associate Professor at Department of Medicine
University Kebangsaan Malaysia Medical Center
Kuala Lumpur, Malaysia
MedicalResearch.com: What is the background for this study?
Response: We commonly observed poor dietary pattern and multiple food restrictions imposed on atopic dermatitis (AD) children by their parents in our daily clinical practice. Food allergy is often associated with AD, however excessive and medically unsubstantiated restriction may lead to various health issues. AD is a chronic skin disease, like any other chronic diseases it affects an individual’s general health. Growth and development are key measures of health in children. We embarked on this study as we were very worried of the consequences of medically unsupervised food restriction, especially those with severe disease. We were concerned about how our atopic dermatitis children are eating and how to help them.
Dr. Kooraki[/caption]
Soheil Kooraki MSR MS, MD
on behalf of Dr. Ali Gholamrezanezhad MD and co-authors
Department of Radiological Sciences,
David Geffen School of Medicine, University of California at Los Angeles
Los Angeles, California
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: COVID19 is a novel strain of the coronavirus family causing pneumonia. Two similar strains were discovered in 2003 and 2012 to cause the so-called SARS and MERS outbreaks, respectively. Radiologists need to be prepared for the escalating incidence of COVID-19. We reviewed the literature to extract the epidemiologic and imaging features of SARS and MERS in comparison with known imaging features of COVID-19 pneumonia to have a better understanding of the imaging features of the COVID19 pneumonia in acute and post-recovery stages.

